ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Status:
RECRUITING
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
The objective of this randomized controlled clinical trial is to evaluate the efficacy of ctDNA-guided rechallenge with cetuximab plus trifluridine/tipiracil compared with bevacizumab plus trifluridine/tipiracil in patients with treatment-refractory, RAS/BRAF wild-type metastatic colorectal cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Bevacizumab Cetuximab trifluridine tipiracil drug combination